In conclusion, our study revealed that EGFR-TKIs seems to have an excellent control of LM in NSCLC patients with EGFR mutations even if WBRT is not delivered; on the other hand, WBRT seems to positively influence the survival of these patients even if it does not get the statistical significance. Here, EGFR is linked to non-small cell lung carcinoma.